An open trial of OKT3 in patients with multiple sclerosis

We report our experience with treatment with Muromonab-CD3 (Orthoclone OKT3) of 16 patients with multiple sclerosis (MS) who were in a progressive phase of their disease (n = 13) or in an acute severe attack lasting longer than 1 month without recovery (n = 3). We induced acute severe T-cytopenia with OKT3. Fifteen patients completed treatment for 10 days. Side effects were common and severe and included hypotension, nausea and vomiting, diarrhea, fever, and myalgia. In two of two patients tested, there was a transient though major rise in the levels of interferon gamma and tumor necrosis factor in the first 12 hours of treatment. Nonetheless, we did not detect new clinical or MRI activity of MS during the period of treatment, although many patients deteriorated transiently in disability scores. At the conclusion of follow-up, only four patients had deteriorated by 1.0 or more points on the Expanded Disability Status Scale of Kurtzke (EDSS) (73% stabilization rate). Of those patients who deteriorated, two died of complications of MS (EDSS 10). Only two patients had clinical improvement at 1 year follow-up. The attendant toxicity of OKT3 makes it unlikely that it will play a major role in the treatment of MS.

[1]  P. Y. Paterson,et al.  Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. , 1969, Journal of immunology.

[2]  G. Lamoureux,et al.  Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis , 1974, Neurology.

[3]  A. Meshorer,et al.  Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. , 1974, Clinical immunology and immunopathology.

[4]  S. Levine,et al.  Suppression of the hyperacute form of experimental allergic encephalomyelitis by drugs. , 1977, Archives internationales de pharmacodynamie et de therapie.

[5]  D. McLean,et al.  Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up , 1978, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[6]  H. Wiśniewski,et al.  The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs , 1979, Journal of the Neurological Sciences.

[7]  J. D. De Mey,et al.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. , 1980, Journal of immunology.

[8]  T. Chang,et al.  Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Mcdevitt,et al.  In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. L. Abreu,et al.  Suppression of experimental allergic encephalomyelitis by interferon. , 1982, Immunological communications.

[11]  M. Cuzner,et al.  The effect of cyclosporin A on the adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat. , 1982, Clinical and experimental immunology.

[12]  L. Chatenoud,et al.  Human in vivo antigenic modulation induced by the anti‐T cell OKT3 monoclonal antibody , 1982, European journal of immunology.

[13]  J. Mussini,et al.  [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[14]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[15]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[16]  M. Waldor,et al.  Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. , 1985, Science.

[17]  A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. , 1985, The New England journal of medicine.

[18]  E. Reinherz,et al.  Immunologic responses of progressive multiple sclerosis patients treated with an anti‐T‐cell monoclonal antibody, anti‐T12 , 1986, Neurology.

[19]  T. Pozzan,et al.  Antibody-induced modulation of the CD3/T cell receptor complex causes T cell refractoriness by inhibiting the early metabolic steps involved in T cell activation , 1987, The Journal of experimental medicine.

[20]  A. Cosimi.  OKT3: First-dose safety and success. , 1987, Nephron.

[21]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.

[22]  J. Bluestone,et al.  Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. , 1988, Journal of immunology.

[23]  Immunosuppression with monoclonal antibodies in multiple sclerosis , 1988, Neurology.

[24]  B. Weinshenker,et al.  Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. , 1989, Journal of the American Academy of Dermatology.

[25]  M. R. Mickey,et al.  A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis , 1989, Neurology.

[26]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.